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Objectives
We provide the first estimate of HIV prevalence among trans and gender-diverse people living in
England and compare outcomes of people living with HIV according to gender identity.
Methods
We analysed a comprehensive national HIV cohort and a nationally representative self-reported
survey of people accessing HIV care in England (Positive Voices). Gender identity was recorded
using a two-step question co-designed with community members and civil society. Responses were
validated by clinic follow-up and/or self-report. Population estimates were obtained from national
government offices.
Results
In 2017, HIV prevalence among trans and gender-diverse people was estimated at 0.46–4.78 per
1000, compared with 1.7 (95% credible interval: 1.6–1.7) in the general population. Of 94 885
people living with diagnosed HIV in England, 178 (0.19%) identified as trans or gender-diverse.
Compared with cisgender people, trans and gender-diverse people were more likely to be London
residents (57% vs. 43%), younger (median age 42 vs. 46 years), of white ethnicity (61% vs. 52%),
under psychiatric care (11% vs. 4%), to report problems with self-care (37% vs. 13%), and to have
been refused or delayed healthcare (23% vs. 11%). Antiretroviral uptake and viral suppression were
high in both groups.
Conclusions
HIV prevalence among trans and gender-diverse people living in England is relatively low
compared with international estimates. Furthermore, no inequalities were observed with regard to
HIV care. Nevertheless, trans and gender-diverse people with HIV report poorer mental health and
higher levels of discrimination compared with cisgender people.
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Introduction
The terms ‘transgender (trans)’ and ‘gender-diverse’ are
used to refer to people who identify as a different gender
from the sex (male/female) they were assigned at birth.
This gender may be either man or woman, or a gender
that does not fit into the existing cultural binary cate-
gorisation (such as genderqueer or non-binary). By con-
trast, ‘cisgender (cis)’ refers to people who identify with
the gender they were assigned at birth.
There is a dearth of data regarding the size of the trans
and gender-diverse population in the UK, with recent
‘tentative’ estimates in the range 200 000–500 000 [1],
equating to around 168 000–420 000 people in England.
No estimates of HIV prevalence among trans and gen-
der-diverse people exist in the UK [2]. In a meta-analysis
from limited studies in 15 countries (not including the
Correspondence: Mr Peter D Kirwan, Blood Safety, Hepatitis, Sexually
Transmitted Infections and HIV Division, Public Health England, 61 Colin-
dale Avenue, London NW9 5EQ, UK. Tel: 020 832 77550; fax: 020 8200
7868; e-mail: peter.kirwan@phe.gov.uk
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.
1
DOI: 10.1111/hiv.12987
© 2020 Crown Copyright. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association HIV Medicine (2020)
ORIGINAL RESEARCH
UK), it was suggested that up to one in five trans women
may be living with HIV worldwide, with researchers call-
ing for improved population estimates of trans people as
well as HIV prevalence studies with larger sample sizes
[3]. Meanwhile, even more limited information on HIV
prevalence exists for trans men (with a few studies pri-
marily in the United States [4,5]) and there are no data
for non-binary and other gender-diverse people. These
groups may be at high risk for HIV acquisition: a 2013
Canadian study showed that up to 60% of trans men may
identify as men who have sex with men (MSM), with
10% engaging in high-risk sexual behaviours and 40%
never having had a HIV test [6]. In the UK, MSM are at
greatest risk of HIV, with an estimated 9% [95% credible
interval (CI): 5–16% [7]] unaware of their HIV status in
2017, and trans MSM who engage in unprotected sex
with cis MSM may be particularly at risk of HIV and
other sexually transmitted infections (STIs) [8].
Trans and gender-diverse people may also have poorer
access to HIV testing, and poorer clinical outcomes than
their cis counterparts. Studies in the United States have
found trans men and women to be insufficiently reached
by HIV testing measures, and consequently more likely to
be diagnosed at a late stage [9,10]. Trans women living
with HIV report lower levels of antiretroviral treatment
(ART) uptake and adherence than cis men and women
[11–15], and trans men and women achieve lower rates
of viral suppression [15,16]. These measures are context-
specific, however, and may not translate to other coun-
tries.
Worldwide, few studies of psychosocial issues, includ-
ing stigma and mental health issues, experienced by
those living with HIV have included trans and gender-di-
verse respondents. In the UK, trans people who completed
The Stigma Survey of People living with HIV 2015
(n = 31) reported higher levels of mental health issues, as
well as greater stigmatization and discrimination com-
pared with cis participants [17]. These findings are con-
sistent with studies in Asia and the Americas which
showed that trans people were at greater risk of mental
health issues, physical abuse, social isolation and eco-
nomic hardship, as well as reporting high levels of stig-
matisation and poorer clinical outcomes [18–21].
In 2015 Public Health England (PHE) worked closely
with LGBTQI and trans community members to develop a
methodology for collecting and validating gender identity
information in national HIV surveillance systems [2]. In
this study, we present the first HIV prevalence estimates
for trans and gender-diverse people living in England
and describe the epidemiology and clinical outcomes of
trans and gender-diverse people living with HIV as com-
pared with cis people.
Methods
HIV surveillance data in the UK are collected, stored and
analysed by PHE, as previously described [22]. Briefly,
since 1982, data on new HIV and AIDS diagnoses in the
UK have been reported by National Health Service (NHS)
laboratories, hospitals and clinics. These data are supple-
mented with clinical updates sent by all HIV outpatient
clinics to create a comprehensive national cohort of peo-
ple diagnosed with HIV [the HIV and AIDS Reporting
System (HARS)]. A linkage algorithm, described elsewhere
[23], was used to match records within and between sys-
tems using a combination of pseudo-anonymized vari-
ables such as Soundex (coded form of the surname) [24],
clinic number, and date of birth.
Until 2014, only binary (male/female) information on
sex was collected, although this information could be
updated if an individual’s gender identity had changed at
their most recent HIV attendance. In 2015, following con-
sultation with members of the trans community and civil
society, it was agreed to collect gender identity and gen-
der assigned at birth information for all people attending
for HIV care using the two-step question shown below
(Box 1).
The Positive Voices survey is a cross-sectional survey
of people attending for HIV care in England & Wales.
Participants were randomly pre-selected to be nationally
representative of all people accessing HIV care. The sur-
vey asked about a range of issues related to living with
HIV and participants were asked to self-report their gen-
der identity and whether this was the same gender
Box 1 Two-step gender identity and gender
assigned at birth question
1. How do you identify your gender?
(1) Man (including trans man)
(2) Woman (including trans woman)
(3) Non-binary
(4) In another way
(5) Prefer not to say




(3) Prefer not to say
© 2020 Crown Copyright. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association HIV Medicine (2020)
2 PD Kirwan et al.
assigned at birth using the two-step question in Box 1.
Responses by participants were linked to their existing
HARS records using a coded identifier. In total, 4357
people attending 72 HIV clinics in England completed the
survey between January and September 2017 [25]. The
Positive Voices study received a favourable ethical opin-
ion by the London-Harrow Research Ethics Committee
(13/LO/0279).
In this study, we determined the number of trans and
gender-diverse people living with diagnosed HIV in Eng-
land in 2017 using linked HARS cohort data (clinician-
reported gender identity) and/or, where available, a
linked Positive Voices survey response (self-reported gen-
der identity). Trans and gender-diverse individuals were
those with a different gender at birth alongside any gen-
der identity (including non-binary, in another way and
prefer not to say). To allow for non-attendance, the
denominator included: people seen for HIV care in 2015
and 2016 (but not 2017) and not known to have died (all
death records are obtained from the Office for National
Statistics), and those seen for care in 2017. People
reported as trans or gender-diverse in HARS without a
linked Positive Voices self-report were followed up with
the reporting clinic for validation.
Data linkage and statistical analyses were performed
using Stata 15.1 (StataCorp, College Station, TX, USA).
Populations were described according to key demographic
and clinical factors. Viral suppression was defined as
having a viral load < 200 copies/mL and those with miss-
ing viral load were assumed not virally suppressed. The
proportion engaged in care was measured as those seen
for HIV care who reattended within 1 year. HIV preva-
lence was calculated per 1000 population using Office for
National Statistics and Government Equalities Office esti-
mates as the denominator [1]. Exact binomial proportion
confidence intervals were calculated.
Results
Of the 94 885 people living with diagnosed HIV in Eng-
land in 2017, 592 (0.62%) were initially reported as hav-
ing a different gender at birth using the two-step
question introduced in 2015. An additional 37 people had
a different gender identity reported during attendances
prior to 2015, whilst 37 people self-reported a different
gender at birth through the Positive Voices survey only.
Following clinic follow-up, 178 were confirmed as having
trans or gender-diverse identities, representing 0.19% of
all people diagnosed with HIV in England in 2017
(Table 1). Based on this numerator and an estimated
168 000–420 000 trans and gender-diverse people living
in England as the denominator, the prevalence of
diagnosed HIV in this population ranged between 0.42
and 1.06 per 1000 population (Table 1). It is of note,
however, that whilst it is based on a much smaller sam-
ple, the Positive Voices 2017 survey results indicate that
up to 800 (37/4357 9 94 885) people living with HIV
may identify as trans or gender-diverse, giving an upper
limit of 4.40 per 1.000 prevalence. Applying the 2017
estimate of undiagnosed HIV infection for all people liv-
ing with HIV of 8% (95% CI: 6–12%) [7], the overall
prevalence of HIV among trans and gender-diverse peo-
ple is estimated to be in the range 0.46–4.78 per 1000 in
2017 (using HARS as the lower bound and Positive
Voices survey results as the upper bound estimates).
Of the 178 confirmed trans and gender-diverse people
with diagnosed HIV, 140 (79%) identified as women or
trans women, 12 (7%) as men or trans men, 20 (11%) as
non-binary, and six (3%) described their gender in
another way. Only two of the 26 people who identified as
non-binary or described their gender in another way were
coded as such in clinician-reported HARS data. The
remaining 24 individuals self-reported this in Positive
Voices.
Compared with cisgender people, trans and gender-di-
verse people living with HIV were more likely to live in
London [57% (102/178) vs. 43% (40 683/94 707)] and to
be of white ethnicity [61% (108/178) vs. 52% (49 350/
94 707)]. Trans and gender-diverse people were also
younger, with more than two-thirds (70%; 124/178) aged
under 50 in 2017 [median age = 42 years, interquartile
range (IQR): 33–52] compared with 63% (59 495/94 707)
of cis people (median = 46 years, IQR: 38–53) (Table 2).
Year of HIV diagnosis for trans and gender-diverse
individuals ranged from 1989 to 2017, with 40% (71/178)
having been first diagnosed in the past 5 years, compared
with a quarter (26%; 24 922/94 707) of cis people. Late
diagnosis rates (diagnosis with a CD4 count < 350 cells/
mm3) in the past 5 years were similar (40% among trans
and gender-diverse people and 42% among cis people).
Table 1 Proportion of people confirmed as trans and gender-di-
verse and estimated diagnosed HIV prevalence for Positive Voices




Denominator 4357 94 885
Proportion confirmed as trans and gender-diverse 0.85% 0.19%




aUsing trans and gender-diverse population size estimate of 168 000–
420 000.
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Table 2 Demographic characteristics of trans and gender-diverse and cis people receiving HIV care in England, 2017
Trans and gender-diverse
(n = 178) Cis (n = 94 707)
N Proportion (95% CI) N Proportion (95% CI)
Gender identity
Male or trans male 12 6.7% (3.5–11.5%) 65 010 68.6% (68.3–68.9%)
Female or trans female 140 78.7% (71.9–84.4%) 29 656 31.3% (31–31.6%)
Non-binary 20 11.2% (7–16.8%) 0 0% (0–0%)
In another way (gender-diverse) 5 2.8% (0.9–6.4%) 0 0% (0–0%)
Prefer not to say/not reported 1 0.6% (0–3.1%) 41 0% (0–0.1%)
Exposure to HIV
Sexual contact 168 94.4% (89.9–97.3%) 87 345 92.2% (92.1–92.4%)
Injecting drug use 1 0.6% (0–3.1%) 1703 1.8% (1.7–1.9%)
Other 3 1.7% (0.3–4.8%) 3054 3.2% (3.1–3.3%)
Not known 6 3.4% (1.2–7.2%) 2605 2.8% (2.6–2.9%)
Ethnicity
White 108 60.7% (53.1–67.9%) 49 350 52.1% (51.8–52.4%)
Black or Black British 21 11.8% (7.5–17.5%) 34 114 36% (35.7–36.3%)
Asian or Asian British 14 7.9% (4.4–12.8%) 3679 3.9% (3.8–4%)
Other/mixed 30 16.9% (11.7–23.2%) 5644 6% (5.8–6.1%)
Not known 5 2.8% (0.9–6.4%) 1920 2% (1.9–2.1%)
Country of birth
UK 64 36% (28.9–43.5%) 38 403 40.5% (40.2–40.9%)
Outside UK 85 47.8% (40.2–55.4%) 46 912 49.5% (49.2–49.9%)
Not known 29 16.3% (11.2–22.6%) 9392 9.9% (9.7–10.1%)
Age in 2017 (years)
< 15 0 0% (0–2.1%) 476 0.5% (0.5–0.5%)
15–24 5 2.8% (0.9–6.4%) 2850 3% (2.9–3.1%)
25–34 45 25.3% (19.1–32.3%) 13 123 13.9% (13.6–14.1%)
35–49 74 41.6% (34.2–49.2%) 43 046 45.5% (45.1–45.8%)
50–64 46 25.8% (19.6–32.9%) 29 908 31.6% (31.3–31.9%)
65+ 8 4.5% (2–8.7%) 5304 5.6% (5.5–5.7%)
Year of HIV diagnosis
2013–2017 71 39.9% (32.6–47.5%) 24 922 26.3% (26–26.6%)
2008–2012 36 20.2% (14.6–26.9%) 23 072 24.4% (24.1–24.6%)
2003–2007 33 18.5% (13.1–25%) 24 169 25.5% (25.2–25.8%)
1998–2002 19 10.7% (6.6–16.2%) 13 125 13.9% (13.6–14.1%)
1993–1997 14 7.9% (4.4–12.8%) 6131 6.5% (6.3–6.6%)
< 1993 5 2.8% (0.9–6.4%) 3288 3.5% (3.4–3.6%)
Place of residence
London 102 57.3% (49.7–64.7%) 40 683 43% (42.6–43.3%)
Outside London 76 42.7% (35.3–50.3%) 54 024 57% (56.7–57.4%)
HIV treatment information (at latest attendance)
On ART 172 96.6% (92.8–98.8%) 91 388 96.5% (96.4–96.6%)
Not on ART 6 3.4% (1.2–7.2%) 3288 3.5% (3.4–3.6%)
Virological suppression (at latest attendance, among those on treatment)
Viral load < 200 copies/mL 150 87.2% (81.3–91.8%) 76 025 83.2% (82.9–83.4%)
Viral load ≥ 200 copies/mL or missing 22 12.8% (8.2–18.7%) 15 363 16.8% (16.6–17.1%)
Virological suppression (at latest attendance, among those on treatment, excluding missing)
Viral load < 200 copies/mL 150 98.7% (95.3–99.8%) 76 025 96.2% (96.1–96.3%)
Viral load ≥ 200 copies/mL 2 1.3% (0.2–4.7%) 3002 3.8% (3.7–3.9%)
Late HIV diagnosis (of those diagnosed 2013–17)
CD4 count < 350 cells/mm3 within 3 months of HIV diagnosis 16 40% (24.9–56.7%) 9081 41.5% (40.9–42.2%)
CD4 count ≥ 350 cells/mm3 within 3 months of HIV diagnosis 24 60% (43.3–75.1%) 12 792 58.5% (57.8–59.1%)
Engagement in care (seen 2015 and re-engaged in 2016)
Engaged in care 138 92% (86.4–95.8%) 77 584 94.5% (94.3–94.6%)
Not engaged in care 12 8% (4.2–13.6%) 4531 5.5% (5.4–5.7%)
Two-year engagement in care (seen 2015 and re-engaged in 2016 or 2017)
Engaged in care 139 92.7% (87.3–96.3%) 78 897 96.1% (95.9–96.2%)
Not engaged in care 11 7.3% (3.7–12.7%) 3218 3.9% (3.8–4.1%)
HIV care complexities (any point during 2015–17)
Active TB and receiving treatment 2 1.1% (0.1–4%) 935 1% (0.9–1.1%)
Current AIDS-defining illness 5 2.8% (0.9–6.4%) 3897 4.1% (4–4.2%)
Chronic viral liver disease and receiving treatment 5 2.8% (0.9–6.4%) 2342 2.5% (2.4–2.6%)
Cancer and receiving treatment 3 1.7% (0.3–4.8%) 1389 1.5% (1.4–1.5%)
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At their most recent attendance, 97% (172/178) of trans
and gender-diverse people were on ART and, of those on
ART, 87% (150/172) had a suppressed viral load [99%
(150/152), excluding those with missing viral load]. The
equivalent proportions for cis people were 96% (91 388/
94 676) and 83% (76 025/91 388) [96% (76 025/79 027),
excluding those with missing viral load], respectively
(Table 2). ART coverage and viral suppression were 96%
(134/140) and 90% (121/134), respectively, for trans
women and 100% (38/38) and 76% (29/38) for trans men,
non-binary and gender-diverse people.
Engagement in care among those seen in 2015 was
92% (138/150) among trans and gender-diverse people
and 94% (77 584/82 115) among cis people. Extending
follow-up by an additional year increased engagement to
93% and 96%, respectively (Table 2). Engagement in care
was 100% (26/26) among non-binary and gender-diverse
people, 91% (104/114) among trans women and 80% (8/
10) among trans men.
Trans and gender-diverse people were more likely than
cis people to be under active psychiatric care (11% vs.
4%), but not for any of the other clinical complexities
captured through HARS (listed in Table 2). Trans and
gender-diverse people were also more likely to be
reported as a current sex worker compared with cis peo-
ple (7% vs. 0.3%) (Table 2).
Of the 37 (0.85% of 4357) respondents in Positive
Voices who identified differently from their gender at
birth: 12 (32%) identified as women or trans women,
none as men or trans men, 19 (51%) as non-binary and
six (16%) described their gender in another way (Table 1).
Trans and gender-diverse respondents were more likely to
report feeling anxious or depressed compared with cis
people (41% moderate to extreme feelings of anxiety or
depression vs. 24%). This group also reported poorer gen-
eral health than cis people (39% rated their health fair to
very bad vs. 27%), were twice as likely to report having
been refused healthcare or having had a medical proce-
dure delayed (23% vs. 11%), and were three times as
likely to report problems with self-care (e.g. washing and
dressing) (37% vs. 13%).
Discussion
This is the first study to estimate HIV prevalence among
trans and gender-diverse people living with HIV in Eng-
land.
Using the available population size estimates for trans
and gender-diverse people in England and comprehensive
national HIV cohort data in combination with self-re-
ported information, we estimate a prevalence of HIV of
0.46–4.78 per 1000 in 2017, with the higher bound
including a higher number of non-binary and gender-di-
verse people. This rate is similar to the HIV prevalence
among the general population in England in 2017 of 1.7
(95% CI: 1.6–1.7) per 1000 and many times lower than
the estimated prevalence among gay and bisexual men,
the group with the highest HIV prevalence in England
[7].
To estimate overall HIV prevalence, it is necessary to
include those living with undiagnosed as well as diag-
nosed HIV. Globally, estimates of undiagnosed HIV
prevalence among trans populations are high compared
with cis populations [3] and many have cited structural
barriers which can prevent or dissuade trans people from
testing and being diagnosed with HIV [26–28]. Even the
assumption that undiagnosed HIV accounts for up to
20% of the burden of HIV in this population in England
would increase the overall HIV prevalence estimate only
slightly, however (0.53–5.50 per 1000).
Population size estimates for trans and gender-diverse
people in the UK split by gender identity were not avail-
able and HIV prevalence for trans men, trans women,
non-binary or other gender-diverse people could not be
directly estimated. Various European studies have
reported a greater proportion of trans women than
trans men, with a 2:1 ratio of trans women to trans
men reported in Sweden and as high as 4:1 in
Table 2 (Continued)
Trans and gender-diverse
(n = 178) Cis (n = 94 707)
N Proportion (95% CI) N Proportion (95% CI)
Severe unstable HIV-associated end organ disease 6 3.4% (1.2–7.2%) 3746 4% (3.8–4.1%)
Under active psychiatric care 19 10.7% (6.6–16.2%) 3883 4.1% (4–4.2%)
Persistent viraemia on ART 0 0% (0–2.1%) 470 0.5% (0.5–0.5%)
Sex worker (any point during 2015–17) 13 7.3% (3.9–12.2%) 260 0.3% (0.2–0.3%)
Prisoner (any point during 2015–17) 0 0% (0–2.1%) 647 0.7% (0.6–0.7%)
ART, antiretroviral therapy; CI, confidence interval; TB, tuberculosis.
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Scotland [29–31]. The ratio of trans women to trans men
living with diagnosed HIV in our study was much higher,
at around 12:1, suggesting a greater prevalence of HIV
among trans women than among trans men.
Globally, estimates of HIV prevalence among trans
women are high; Baral et al. [3] give a pooled estimate of
global HIV prevalence in this population of 19%, or 190
per 1000. In this meta-analysis prevalence was somewhat
higher in the United States, pushing up the global estimate,
and estimate precision varied according to the size of the
study in each country. Among trans women in Australia, a
country with a similar health system and anti-discrimina-
tion laws to England, HIV prevalence was estimated at 45
per 1000 (based on a single clinic audit [32]).
HIV prevalence estimates may be biased by several fac-
tors. For small populations, miscoding and data errors
can have a significant effect. Through clinical follow-up
we discovered that more than three-quarters of patients
initially reported as trans or gender-diverse were incor-
rectly coded, largely due to data entry errors or use of
‘default’ codes. Without such robust follow-up proce-
dures, the number of trans and gender-diverse people liv-
ing with HIV would have been over-estimated in our
study.
The converse is also true: of the 37 trans and gender-
diverse-identifying Positive Voices survey respondents,
nearly all trans women (11/12) were also reported as
trans in their corresponding HARS clinical records; how-
ever, only 1/19 non-binary and 0/6 other gender-diverse
people had their gender identity reported in the same
way in HARS. This suggests that during these early
phases of reporting gender identity, clinic staff may have
focused on reporting trans men and women, and under-
reported non-binary and other gender-diverse people.
Previous studies have shown that under-reporting is often
due to healthcare staff not being aware of or not asking
about gender identity [33]. Less commonly, people may
choose not to disclose their gender identity [34]; how-
ever, these data reinforce the importance of clinic staff
asking patients to answer gender identity questions them-
selves, rather than answering on their behalf.
In this study, we also for the first time presented the
psychosocial and HIV clinical outcomes of trans and gen-
der-diverse people living with diagnosed HIV in England
and compared these with cisgender people. Our findings
indicate that the quality of HIV care in England is excel-
lent for trans and gender-diverse people. This is in keep-
ing with PHE data showing excellent outcomes for people
living with HIV regardless of gender, sexuality and eth-
nicity and geography [7].
For those engaged in care, there was no difference in
ART uptake or viral suppression, which highlights the
high and equitable standard of care provided to people
living with HIV in the UK. Our results are consistent with
those of a cohort study in the United States which found
equal levels of engagement in HIV care among trans
individuals and cis men (slightly higher among cis
women) and similar levels of ART uptake and viral sup-
pression in trans and cis people with HIV [35]. In our
study, engagement in care was only slightly lower among
trans and gender-diverse individuals receiving care than
among cis people, with similar trends seen for 2-year
engagement in care. Maintaining high levels of engage-
ment in care is important; those lost to follow-up are
likely to have interrupted ART and, consequently, are
more likely to have an unsuppressed viral load [36].
There is a risk that engagement in care and ART adher-
ence among trans and gender-diverse people may be
affected by a perception that ART could have a negative
impact upon their hormones [14,37]. It is therefore vital
that clinicians understand the importance of access to
gender-affirming care for this population, including gen-
der-affirming hormone treatment, and the impact of gen-
der-affirming care on HIV care engagement [38,39].
Trans and gender-diverse people with HIV reported
higher levels of anxiety and depression than cis respon-
dents and were three times as likely to be under active
psychiatric care. Whilst this may reflect, in part, an obli-
gation for trans and gender-diverse people to seek psy-
chiatric care for gender-related reasons, it also reflects
higher rates of mental health issues among this group
[18]. It has also been reported that trans people who
access psychiatric care for gender-related reasons may
sometimes be held longer than is necessary [40]. A limi-
tation is that HIV data systems were only able to capture
psychiatric care; it is probable that trans and gender-di-
verse people are also more likely to receive care from a
psychologist, for conditions including gender dysphoria.
Trans and gender-diverse people living with HIV are
also significantly affected by HIV-related stigma: The
People Living with HIV Stigma Survey reported that trans
respondents (n = 31) were significantly more likely than
cis participants (n = 1545) to report worries about verbal
harassment and experience exclusion from family gather-
ings. One in 10 trans participants in this survey reported
physical assault in the preceding year, compared with
one in 25 cis participants [17]. These findings suggest
that HIV-related stigma may be exacerbated by stigma
encountered because of other characteristics.
The two-step measure used in our study suffers from
the limitation that sex at birth for gender-diverse individ-
uals could not be discerned. It may have been advanta-
geous to know the proportions of people assigned male at
birth and those assigned female at birth people in our
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cohort, as their outcomes, experiences of treatment and
risks may well be different. The design of this two-step
measure was informed by community feedback that ask-
ing trans and gender-diverse people directly about sex at
birth is an intrusive question [41]. Whilst other two-step
question formats exist, these may suffer from different
limitations: fewer question responses (due to being per-
ceived as intrusive), diagnostic masking, incorrect
assumptions about a trans or gender-diverse person’s
health needs based on their assigned sex at birth, and
poorer experiences of healthcare services.
The wide range of our prevalence estimate reflects the
considerable uncertainty with which these estimates are
made. As discussed earlier, results of the Positive Voices
survey based on self-report suggest that non-binary and
other gender-diverse people are likely to be under-re-
ported by clinic staff. While clinic follow-up was largely
successful in confirming trans gender identity, greater
awareness of diverse gender identity and how to record
this is required by healthcare staff.
Conclusions
People living with HIV are diverse and HIV clinical care
is of a high standard for all. Once diagnosed, trans and
gender-diverse people enjoy the full benefit of free and
confidential HIV care through the NHS and have excel-
lent clinical outcomes. Clinics should endeavour to be
trans-inclusive, and more widespread use of clinics that
cater specifically to the needs of trans and gender-diverse
people (such as CliniQ, Clinic T and 56T) should be con-
sidered [42–44].
Estimates of HIV prevalence among trans and gender-
diverse people in England are lower than estimates
reported abroad. This may be because of greater access to
free health promotion and HIV testing in the UK, as well
as high rates of viral suppression, which eliminate the
risk of transmission. Trans and gender-diverse people are
still at risk of late HIV diagnosis and associated morbidity
and mortality, however, and targeted testing campaigns
should continue to promote HIV testing among these
populations [45,46].
Trans and gender-diverse people with HIV in England
reported poorer mental health than cis people with HIV
and our results demonstrate the need for ongoing psy-
chosocial support in HIV clinics. Better knowledge and
awareness of trans and gender-diverse populations by
clinical staff will help to improve the reporting of gender
identity data in routine surveillance, leading to improved
understanding of the needs of this population.
The British Association for Sexual Health and HIV
(BASHH) has recently recommended improvements to
trans and gender-diverse inclusion in sexual health clin-
ics [38]. These include the use of a standardized question-
naire for all sexual health and HIV clinic attendees to
self-report their gender identity, a necessary step to avoid
the routine under-reporting of trans and gender-diverse
people.
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